| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Laboratory of Tumor Immunology and Biology and 2 Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Local radiation is an established therapy for human tumors. Radiation also has been shown to alter the phenotype of target tissue, including gene products that may make tumor cells more susceptible to T-cell-mediated immune attack. We demonstrate a biological synergy between local radiation of tumor and active vaccine therapy. The model used consisted of mice transgenic for human carcinoembryonic antigen (CEA) and a murine carcinoma cell line transfected with CEA. The vaccine regimen consisted of a prime and boost strategy using vaccinia and avipox recombinants expressing CEA and three T-cell costimulatory molecules. One dose of 8-Gy radiation to tumor induced up-regulation of the death receptor Fas in situ for up to 11 days. However, neither radiation at this dose nor vaccine therapy was capable of inhibiting growth of 8-day established tumor. When vaccine therapy and local radiation of tumor were used in combination, dramatic and significant cures were achieved. This was mediated by the engagement of the Fas/Fas ligand pathway because Ag-bearing tumor cells expressing dominant-negative Fas were not susceptible to this combination therapy. Following the combination of vaccine and local radiation, tumors demonstrated a massive infiltration of T cells not seen with either modality alone. Mice cured of tumors demonstrated CD4+ and CD8+ T-cell responses specific for CEA but also revealed the induction of high levels of T-cell responses to two other antigens (gp70 and p53) overexpressed in tumor, indicating the presence of a consequential antigen cascade. Thus, these studies demonstrate a new paradigm for the use of local tumor irradiation in combination with active specific vaccine therapy to elicit durable antitumor responses of established tumors.
This article has been cited by other articles:
|
|
 |
|
  Y. Xie, O. Bai, J. Yuan, R. Chibbar, K. Slattery, Y. Wei, Y. Deng, and J. Xiang Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity via Membrane-Bound Transforming Growth Factor-{beta}1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses Cancer Res., October 1, 2009; 69(19): 7756 - 7766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shanker, A. D. Brooks, K. M. Jacobsen, J. W. Wine, R. H. Wiltrout, H. Yagita, and T. J. Sayers Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity Cancer Res., August 15, 2009; 69(16): 6615 - 6623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lee, S. L. Auh, Y. Wang, B. Burnette, Y. Wang, Y. Meng, M. Beckett, R. Sharma, R. Chin, T. Tu, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment Blood, July 16, 2009; 114(3): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti, M. L. Dustin, et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells J. Immunol., September 1, 2008; 181(5): 3099 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Lechleider, P. M. Arlen, K.-Y. Tsang, S. M. Steinberg, J. Yokokawa, V. Cereda, K. Camphausen, J. Schlom, W. L. Dahut, and J. L. Gulley Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant Clin. Cancer Res., August 15, 2008; 14(16): 5284 - 5291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schaue, B. Comin-Anduix, A. Ribas, L. Zhang, L. Goodglick, J. W. Sayre, A. Debucquoy, K. Haustermans, and W. H. McBride T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy Clin. Cancer Res., August 1, 2008; 14(15): 4883 - 4890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Madan, J. L. Gulley, J. Schlom, S. M. Steinberg, D. J. Liewehr, W. L. Dahut, and P. M. Arlen Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy Clin. Cancer Res., July 15, 2008; 14(14): 4526 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chakraborty, E. K. Wansley, J. A. Carrasquillo, S. Yu, C. H. Paik, K. Camphausen, M. D. Becker, W. F. Goeckeler, J. Schlom, and J. W. Hodge The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell-Mediated Killing Clin. Cancer Res., July 1, 2008; 14(13): 4241 - 4249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Garnett, J. Schlom, and J. W. Hodge Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement Clin. Cancer Res., June 1, 2008; 14(11): 3536 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, P. M. Arlen, and J. L. Gulley Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design ASCO Educational Book, January 1, 2008; 2008(1): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schlom, P. M. Arlen, and J. L. Gulley Cancer Vaccines: Moving Beyond Current Paradigms Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hassan, J. Williams-Gould, S. M. Steinberg, D. J. Liewehr, J. Yokokawa, K. Y. Tsang, R. J. Surawski, T. Scott, and K. Camphausen Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts. Clin. Cancer Res., August 15, 2006; 12(16): 4983 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Reits, J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K.Wansley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J. Exp. Med., May 15, 2006; 203(5): 1259 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Tarassoff, P. M. Arlen, and J. L. Gulley Therapeutic vaccines for prostate cancer. Oncologist, May 1, 2006; 11(5): 451 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liu, S. A. Caldwell, K. M. Greeneltch, D. Yang, and S. I. Abrams CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape J. Immunol., March 15, 2006; 176(6): 3374 - 3382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gelbard, C. T. Garnett, S. I. Abrams, V. Patel, J. S. Gutkind, C. Palena, K.-Y. Tsang, J. Schlom, and J. W. Hodge Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. Clin. Cancer Res., March 15, 2006; 12(6): 1897 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-X. Wang, S. Shu, and G. E. Plautz Host Lymphodepletion Augments T Cell Adoptive Immunotherapy through Enhanced Intratumoral Proliferation of Effector Cells Cancer Res., October 15, 2005; 65(20): 9547 - 9554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Allegra and R. W. Childs Cytotoxins and Cancer Immunotherapy: The Dance of the Macabre? J Natl Cancer Inst, October 5, 2005; 97(19): 1396 - 1397. [Full Text] [PDF]
|
|
|
|
|
|
J. Yokokawa, C. Palena, P. Arlen, R. Hassan, M. Ho, I. Pastan, J. Schlom, and K. Y. Tsang Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin Clin. Cancer Res., September 1, 2005; 11(17): 6342 - 6351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor J. Immunol., June 15, 2005; 174(12): 7516 - 7523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kudo-Saito, J. Schlom, K. Camphausen, C. N. Coleman, and J. W. Hodge The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors Clin. Cancer Res., June 15, 2005; 11(12): 4533 - 4544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gulley, P. M. Arlen, A. Bastian, S. Morin, J. Marte, P. Beetham, K.-Y. Tsang, J. Yokokawa, J. W. Hodge, C. Menard, et al. Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3353 - 3362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Kaufman Integrating Bench With Bedside: The Role of Vaccine Therapy in the Treatment of Solid Tumors J. Clin. Oncol., February 1, 2005; 23(4): 659 - 661. [Full Text] [PDF]
|
|
|
|
|
|
G. K. Koski and B. J. Czerniecki Combining Innate Immunity With Radiation Therapy for Cancer Treatment Clin. Cancer Res., January 1, 2005; 11(1): 7 - 11. [Full Text] [PDF]
|
|
|
|
|
|
C. T. Garnett, C. Palena, M. Chakarborty, K.-Y. Tsang, J. Schlom, and J. W. Hodge Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes Cancer Res., November 1, 2004; 64(21): 7985 - 7994. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
